AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9132505
Drug: Caffeine (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (125 mg)
Trial: 2947953
Drug: 5 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 micrograms hepatitis B vaccine
Trial: 1535229
Drug: 2 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 micrograms hepatitis B vaccine
Trial: 1535229
Drug: 1 microgram
RxNorm normalized name: Alfacalcidol 1 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 microgram hepatitis B vaccine
Trial: 1535229
Drug: Low anti-HBs
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low anti-HBs titres (10-100 miu/mL)
Trial: 1535229
Drug: Medium anti-HBs
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium anti-HBs titres (101-1000 miu/mL)
Trial: 1535229
Drug: High anti-HBs
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High anti-HBs levels (greater than 1000 miu/mL)
Trial: 6707051
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g gentamicin base per 40 g pack of powdered polymer
Trial: 6707051
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g gentamicin base per 40 g pack of powdered polymer
Trial: 22675960
Drug: alfentanil 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfentanil 10 microg/kg IV with propofol 0.7 mg/kg IV
Trial: 22675960
Drug: ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketamine 0.5 mg/kg IV with propofol 0.7 mg/kg IV
Trial: 20367516
Drug: Aquatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquatic therapy (6 sessions, once weekly for 30 min over 6-8 weeks)
Trial: 18586313
Drug: Current hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Current hormone therapy use
Trial: 8446743
Drug: Placebo (saline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline, 5.4 ml/hr)
Trial: 3011834
Drug: T4 treatment
RxNorm normalized name: T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: T4 treatment group (L-T4 1.5 micrograms/kg iv daily for 2 weeks)
Trial: 3011834
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no T4 treatment)
Trial: 27641143
Drug: Romosozumab (210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romosozumab (210 mg subcutaneous injections monthly for 12 months)
Trial: 27641143
Drug: Placebo (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (subcutaneous injections monthly for 12 months)
Trial: 20492573
Drug: Fentanyl buccal
RxNorm normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl buccal soluble film (800 microg) administered as a single film
Trial: 20492573
Drug: Fentanyl buccal
RxNorm normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl buccal soluble film (200 microg) administered as four separate films simultaneously
Trial: 20492573
Drug: Injectable fentanyl
RxNorm normalized name: fentanyl Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable fentanyl citrate (200 microg) administered by intravenous infusion
Trial: 20492573
Drug: Injectable fentanyl
RxNorm normalized name: fentanyl Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable fentanyl citrate (800 microg/16 mL) administered orally
Trial: 10520076
Drug: Active grass
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active grass pollen immunotherapy
Trial: 8904617
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg LY293111 three times daily for 8 days
Trial: 8904617
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg LY293111 three times daily for 8 days
Trial: 8904617
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg LY293111 twice daily for 8 days
Trial: 6394044
Drug: Experiential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experiential treatment
Trial: 6394044
Drug: Didactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didactic treatment
Trial: 6394044
Drug: Non-conscious treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-conscious treatment
Trial: 26887958
Drug: Antenatal depression-oriented
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal depression-oriented acupuncture (weekly 1-hour treatments for 8 weeks from 24 to 31 weeks of gestation)
Trial: 24804638
Drug: Embrace Advanced
RxNorm normalized name: Zembrace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Embrace Advanced Scar Therapy device
Trial: 20228401
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy targeting systolic pressure <120 mm Hg
Trial: 20228401
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy targeting systolic pressure <140 mm Hg
Trial: 7033015
Drug: Indomethacin 100
RxNorm normalized name: indomethacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 100 mg suppository
Trial: 6991534
Drug: Aspirin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (1000 mg)
Trial: 12188410
Drug: Chamomile extract
RxNorm normalized name: Chamomile Extract
DrugBank: Chamomile (DB14357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chamomile extract spray (111 mg)
Trial: 10650360
Drug: Periostat (subantimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periostat (subantimicrobial dose of doxycycline) in conjunction with scaling and root planing (SRP)
Trial: 2240675
Drug: Clonidine 5
RxNorm normalized name: apraclonidine 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 5 micrograms.ml‐1 (group C‐5)
Trial: 2240675
Drug: Clonidine 10
RxNorm normalized name: apraclonidine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 10 micrograms.ml‐1 (group C‐10)
Trial: 2240675
Drug: Epinephrine 5
RxNorm normalized name: epinephrine 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine 5 micrograms.ml‐1 (group E)
Trial: 25514064
Drug: Dexmecamylamine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmecamylamine (1 to 4 mg adjunct to SSRI/SNRI)
Trial: 23435622
Drug: Enzastaurin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzastaurin (500 mg/day) with docetaxel (75 mg/m²) and prednisone (10 mg daily)
Trial: 23435622
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with docetaxel (75 mg/m²) and prednisone (10 mg daily)
Trial: 22231005
Drug: Effervescent tablets
RxNorm normalized name: Hydralyte Effervescent Tablets Berry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent tablets (Corega Tabs)
Trial: 22231005
Drug: Association of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Association of effervescent tablets and ultrasonic device
Trial: 17439507
Drug: Oligofructose-enriched inulin
RxNorm normalized name: Inulin
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oligofructose-enriched inulin (12 g/day, p.o.)
Trial: 17439507
Drug: Placebo (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (12 g/day of maltodextrin, p.o.)
Trial: 16749287
Drug: Early mechanical
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early mechanical revascularization with platelet glycoprotein IIb/IIIa inhibitors and drug-eluting stents, associated with strict glycemic control during hospital stay
Trial: 10548198
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (NO) at 20 ppm for 20 minutes
Trial: 1959392
Drug: NCPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCPAP treatment correcting apneas, sleep fragmentation, and hypoxemia
Trial: 1959392
Drug: NCPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCPAP treatment correcting apneas and sleep fragmentation while inducing intermittent hypoxemia
Trial: 1959392
Drug: NCPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCPAP treatment under hypoxemic conditions
Trial: 24239030
Drug: Interim methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interim methadone (IM; methadone without counseling) for the first 4 months of 12 months of methadone treatment
Trial: 22857721
Drug: Heme arginate
RxNorm normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heme arginate (1 mg/kg body weight)
Trial: 17003815
Drug: Vasopressin (non-pressor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasopressin (non-pressor dose)
Trial: 11849459
Drug: Glycine betaine
RxNorm normalized name: Glycine betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycine betaine (GB) 4-g daily
Trial: 11783251
Drug: Shenqi Fuzheng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenqi Fuzheng Injection (SQFZI) combined with chemotherapy (Group A)
Trial: 8033606
Drug: Chemotherapy (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (Group B)
Trial: 11783251
Drug: Shenqi Fuzheng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenqi Fuzheng Injection (SQFZI) (Group C)
Trial: 2194894
Drug: 500-mL gastric
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500-mL gastric bubble (Ballobes) as an adjunct to diet, physical training, and behavioral modification
Trial: 12468954
Drug: Otilonium bromide
RxNorm normalized name: otilonium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otilonium bromide (40 mg, three times daily)
Trial: 2583897
Drug: Oral L-Phe
RxNorm normalized name: L-Formula Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral L-Phe (100 mg/kg) + UVA exposure
Trial: 2583897
Drug: Oral L-Phe
RxNorm normalized name: L-Formula Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral L-Phe (100 mg/kg) + UVA exposure + topical 10% L-Phe cream
Trial: 25459096
Drug: Oxygen +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen + oral analgesics
Trial: 24101747
Drug: Mindfulness-based course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based course (MBC) with eight weekly sessions of mindfulness education
Trial: 17882008
Drug: Transdermal patch
RxNorm normalized name: TRANSDERMAL PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal patch releasing 14 microg of E2 per day
Trial: 15756271
Drug: 350 mg
RxNorm normalized name: hemin 350 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 mg m(‐2) irinotecan (Group A)
Trial: 15756271
Drug: 250, 350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250, 350 or 500 mg m(‐2) irinotecan based on individual patient tolerance (Group B)
Trial: 15756271
Drug: Individual dose
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual dose escalation based on risk factor optimisation (Group C)
Trial: 12359676
Drug: Paroxetine (to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (to 60 mg/day)
Trial: 12359676
Drug: Desipramine (to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (to 30 mg/day)
Trial: 7841427
Drug: Rifabutin 150
RxNorm normalized name: rifabutin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifabutin 150 mg
Trial: 7841427
Drug: Rifabutin 300
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifabutin 300 mg
Trial: 2158257
Drug: Rifabutin 450
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifabutin 450 mg
Trial: 30684325
Drug: Metformin and
RxNorm normalized name: metformin and acarbose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and pioglitazone
Trial: 29786570
Drug: Metformin and
RxNorm normalized name: metformin and acarbose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and sulfonylureas
Trial: 18723286
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (0.1mg/kg)
Trial: 18723286
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (0.025mg/kg)
Trial: 18723286
Drug: Naloxone (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (after morphine administration)
Trial: 15494904
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (flucloxacillin or vancomycin)
Trial: 8327367
Drug: Oral amoxicillin
RxNorm normalized name: amoxicillin Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin administered 1 hr prior to the procedure
Trial: 8327367
Drug: Flavored syrup
RxNorm normalized name: Oral Syrup (Flavored Syrup Vehicle)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavored syrup as placebo
Trial: 2423813
Drug: Partially purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partially purified bean-derived amylase inhibitor with 50 g of starch
Trial: 30357819
Drug: Revascularization together
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Revascularization together with Best Medical Therapy (BMT)
Trial: 30357819
Drug: Best Medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best Medical Therapy (BMT) alone
Trial: 21083671
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol 400 mg
Trial: 18329221
Drug: Modafinil (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (400 mg/day, n = 14)
Trial: 18329221
Drug: Mirtazapine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (60 mg/day, n = 13)
Trial: 18329221
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (pericyazine, 2.5‐10 mg/day, n = 22)
Trial: 12909071
Drug: Oral amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amiodarone plus oral verapamil (group A+V)
Trial: 12909071
Drug: Oral flecainide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral flecainide plus oral verapamil (group F+V)
Trial: 12909071
Drug: Oral amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amiodarone (group A)
Trial: 12909071
Drug: Oral flecainide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral flecainide (group F)
Trial: 11286371
Drug: Medical Resonance
RxNorm normalized name: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical Resonance Therapy Music (MRT-Music), 3 x 30 minutes per day for 14 days
Trial: 8803961
Drug: Lacidipine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacidipine (2 mg b.i.d. for 8 weeks)
Trial: 1395455
Drug: OB +
RxNorm normalized name: RE OB + DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OB + DZ (20 mg + 2 mg) T.I.D.
Trial: 1395455
Drug: OB alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OB alone (20 mg)
Trial: 30344180
Drug: Intravenous human
RxNorm normalized name: botulism immune globulin IV human Injection [BabyBIG]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous human albumin solution (HAS) administered to target serum albumin level of ≥35 g/L for up to 14 days or until discharge.
Trial: 27633687
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (enoxaparin) prophylaxis
Trial: 11146780
Drug: Adjuvant chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemoradiotherapy (45 Gy concurrent radiotherapy and fluorouracil 225‐250 mg/m(2) per day for 5 weeks)
Trial: 25543183
Drug: Prism adaptation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prism adaptation (PA) therapy
Trial: 21961489
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of metformin hydrochloride (1,000 mg)
Trial: 21961489
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of metformin hydrochloride (1,000 mg)
Trial: 16143129
Drug: ursodeoxycholic acid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ursodeoxycholic acid, 8‐10 mg/kg body weight daily (n = 42)
Trial: 16143129
Drug: cholestyramine, 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cholestyramine, 8 g daily (n = 42)
Trial: 12392588
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg caffeine (C-replete)
Trial: 8076228
Drug: ondansetron (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron (5 mg.m‐2)
Trial: 8076228
Drug: metoclopramide (0.12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoclopramide (0.12 mg.kg‐1)
Trial: 7944878
Drug: placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (saline solution)
Trial: 2574554
Drug: Terfenadine 120
RxNorm normalized name: terfenadine 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine 120 mg once daily (qd)
Trial: 2574554
Drug: Terfenadine 60
RxNorm normalized name: terfenadine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine 60 mg twice daily (bid)
Trial: 20626269
Drug: Raloxifene with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene with antiplatelet agents
Trial: 20626269
Drug: Raloxifene without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene without antiplatelet agents
Trial: 10607813
Drug: High-dose rhuMAb‐E25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rhuMAb‐E25 (5.8 microg/kg/nanogram IgE/mL)
Trial: 10607813
Drug: Low-dose rhuMAb‐E25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose rhuMAb‐E25 (2.5 microg/kg/nanogram IgE/mL)
Trial: 20145608
Drug: Probiotic (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic (2 capsules per day)
Trial: 20145608
Drug: Probiotic (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic (1 capsule + 1 placebo capsule per day)
Trial: 331057
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 capsules per day)
Trial: 9856652
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion 5-fluorouracil (5FU)
Trial: 9856652
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion 5-fluorouracil with paclitaxel
Trial: 2691808
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg Quazepam (QZP) for 8 weeks
Trial: 603221
Drug: Practolol (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practolol (0.2 mg/kg body weight) with atropine (0.01 mg/kg body weight)
Trial: 31809985
Drug: Omega-3 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 (oral Omega-3 2 g twice daily)
Trial: 31292183
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg thiamine (control)
Trial: 31292183
Drug: 1.2 mg
RxNorm normalized name: RNA 1.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mg thiamine
Trial: 31292183
Drug: 2.4 mg
RxNorm normalized name: pectin 2.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 mg thiamine
Trial: 31292183
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg thiamine
Trial: 28167007
Drug: Sinuclean Nebules
RxNorm normalized name: Sinucleanse
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sinuclean Nebules treatment administered by nasal douche (Rinowash) twice/day for 10 days
Trial: 28167007
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline administered by nasal douche (Rinowash) twice/day for 10 days
Trial: 16440357
Drug: Preemptive lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Preemptive lamivudine therapy (100 mg daily from the start of TACL)
Trial: 16440357
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no lamivudine therapy)
Trial: 9132982
Drug: Clotrimazole vaginal
RxNorm normalized name: Clotrimazole Vaginal Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole vaginal tablets (2 x 100 mg once a day for 7 days)
Trial: 9132982
Drug: AVC suppositories
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVC suppositories (1.05 g sulfanilamide, 14 mg aminacrine hydrochloride, 140 mg allantoin twice a day for 7 days)